检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:张文将[1,2] 易健 刘柏炎[1] ZHANG Wenjiong;YI Jian;LIU Baiyan(Hu'nan University of Chinese Medicine,Hu'nan Province,Changsha 410208,China;Yiyang Medical College,Hu'nan Province,Changsha 413000,China)
机构地区:[1]湖南中医药大学,湖南长沙410208 [2]益阳医学高等专科学校,湖南益阳413000
出 处:《中国医药导报》2018年第27期30-33,37,共5页China Medical Herald
基 金:湖南省中医药科研计划项目(201870);湖南省教育厅优秀青年项目(17B271);湖南省自然科学基金资助项目(2018JJ2412)
摘 要:动脉粥样硬化(AS)是各种心脑血管疾病的病理基础,严重威胁着人类的健康,近年来炎症学说受到了越来越多学者的重视,从抗炎及免疫调节角度探讨抗AS是一种新思路,在炎症演变过程中,有多条信号通路参与其中,深入研究信号通路,有望成为动脉粥样硬化药物研究干预靶点。本文从分子生物学水平总结前瞻性的基础研究进展,以期给AS及其相关疾病的治疗带来启发。Atherosclerosis (AS) is the pathological basis of cardiovascular disease, which is a serious threat to human health. In recent years, more and more scholars pay attention to the theory of inflammation. It is a new idea to treat AS front the point of view with antiinflammation and immunoregulation. There are muhiple signal transduction pathways in- volved in the course of inflammation progress. The signaling pathway is studied deeply that is expected to become a tar- get for intervention of atherosclerosis drugs. This article summerizes the prospective basic experimental from cellular and molecular level, to bring about inspiration in the treatment of AS and AS related diseases.
分 类 号:R543.12[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:3.15.238.90